Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278399 | 0.66 | MAOA (0.42) | MAPTL3MBTL1RAB9ANPC1POLB | |
| SCHEMBL7113456 | 0.62 | HSP90AA1 (0.47) | MAPTL3MBTL1RAB9ANPC1POLB | |
| SCHEMBL249997 | 0.61 | CES1 (0.45) | MAPTRAB9ANPC1POLBMEN1 | |
| SCHEMBL29385734 | 0.61 | CES1 (0.45) | MAPTRAB9ANPC1POLBMEN1 | |
| SCHEMBL31212788 | 0.61 | NOTUM (0.33) | — | |
| Bromide SCHEMBL8559693 | 0.60 | — | — | |
| SCHEMBL375596 | 0.60 | ADORA3 (0.47) | MAPTL3MBTL1RAB9ANPC1POLB | |
| SCHEMBL6487919 | 0.60 | CES1 (0.43) | MAPTRAB9ANPC1POLBMEN1 | |
| Hydrochloric Acid SCHEMBL2710070 | 0.60 | MEN1 (0.43) | MAPTRAB9ANPC1POLBMEN1 | |
| SCHEMBL30676949 | 0.60 | CES1 (0.43) | MAPTRAB9ANPC1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | claimed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | claimed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-0851756-B1 | USE OF ONDANSETRON IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TREMOR | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | disclosed |
| EP-1239882-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | MAPT 3276/4885L3MBTL1 1623/4885RAB9A 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.